The Society of Toxicology (SOT) brought together more than 5,000 people for its 63rd Annual Meeting and ToxExpo March 10 – 24 in Salt Lake City, Utah. Five members of the AxoSim team attended the […]
Read MoreMore than 300 million people globally live with a rare disease, and just 100,000 live with Guillain–Barré Syndrome (GBS). Rare Disease Day is observed annually on the last day of February to increase awareness of […]
Read MoreAxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors —Serial Entrepreneurs Dale Pfost and David Weiner Bring Broad Expertise as AxoSim Expands Its Leadership in Human Organoid Technologies Designed to Make […]
Read MoreRESEARCH As Vyant Bio continues its wind-down, the neuroscience research assets of its subsidiary StemoniX have officially been picked up by AxoSim, a New Orleans-based drug discovery biotech. In an Oct. 24 press release, AxoSim said […]
Read MoreOn Tuesday, October 24, 2023, AxoSim announced the completion of its acquisition of the microBrain™-associated assets of Vyant Bio’s StemoniX subsidiary—news of the acquisition generated excitement among the scientific, pharmaceutical, and business communities. From The […]
Read MoreNew Orleans, La. ─ October 24, 2023 ─ AxoSim, Inc., a leader in the development and application of live biomimetic human drug discovery platforms for neurological diseases, today announced completion of its acquisition of the microBrain™-associated assets of […]
Read MoreWIRED recently quoted our Co-Founder Michael J. Moore and mentioned AxoSim and our 3D peripheral nerve model. The article highlights 3d printing of living brain cells from a team of scientists at Monash University. Excerpt […]
Read MoreTell us the school you attend, grade level and major. I am currently a senior at Tulane University majoring in cell and molecular biology. Why did you want to intern with us at AxoSim? While […]
Read MoreAxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio’s StemoniX Assets —Combines Three Leading Human Biomimetic Organoid Platform Technologies for Neurological Drug Discovery— —AxoSim Gains microBrainTM Intellectual Property from StemoniX, Along With Expert Scientific […]
Read MoreOn the Road with AxoSim’s Conference Team | Q&A with Senior Business Development Manager Chelsea Richardson What upcoming conferences is AxoSim a part of this summer? A portion of our team will be headed to […]
Read More